MedPath

Oral administration of diclofenac in the prevention of post-ERCP pancreatitis: A double-blind, multicenter study.

Not Applicable
Conditions
post-ERCP pancreatitis
Registration Number
JPRN-UMIN000008109
Lead Sponsor
The 4th department of internal medicine, Sapporo Medical University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
430
Inclusion Criteria

Not provided

Exclusion Criteria

1) Patients with hypersensitivity to diclofenac. 2) Patients with performance status 4. 3) Patients who are treated with diclofenac or received diclofenac within a week. 4) Patients with a history of EST and EPBD. 5) Patients with Vater tumor 6) Patients with divism 7) Patients with chronic pancreatitis 8) Patients with biliary pancreatitis 9) Patients who are judged inappropriate by chief (responsive) medical examiner.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
incidence rate of post-ERCP pancreatitis
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath